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ABSTRACT

Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging aimed to
recruit 1000 individuals aged over 60 to assist with prospective research into Alzheimer’s disease (AD). This
paper describes the recruitment of the cohort and gives information about the study methodology, baseline
demography, diagnoses, medical comorbidities, medication use, and cognitive function of the participants.
Methods: Volunteers underwent a screening interview, had comprehensive cognitive testing, gave 80 ml of
blood, and completed health and lifestyle questionnaires. One quarter of the sample also underwent amyloid
PET brain imaging with Pittsburgh compound B (PiB PET) and MRI brain imaging, and a subgroup of 10%
had ActiGraph activity monitoring and body composition scanning.
Results: A total of 1166 volunteers were recruited, 54 of whom were excluded from further study due to
comorbid disorders which could affect cognition or because of withdrawal of consent. Participants with
AD (211) had neuropsychological profiles which were consistent with AD, and were more impaired than
participants with mild cognitive impairment (133) or healthy controls (768), who performed within expected
norms for age on neuropsychological testing. PiB PET scans were performed on 287 participants, 100 had
DEXA scans and 91 participated in ActiGraph monitoring.
Conclusion: The participants comprising the AIBL cohort represent a group of highly motivated and wellcharacterized individuals who represent a unique resource for the study of AD. They will be reassessed at
18-month intervals in order to determine the predictive utility of various biomarkers, cognitive parameters
and lifestyle factors as indicators of AD, and as predictors of future cognitive decline.
Key words: Alzheimer’s disease, mild cognitive impairment, healthy controls, cohort study, longitudinal study, PiB PET imaging
Correspondence should be addressed to: Kathryn A. Ellis, Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, St. Vincent’s
Aged Psychiatry Service, St George’s Hospital Campus, 283 Cotham Rd, Kew, Victoria 3101, Australia. Phone: +61 3 9389 2919; Fax +61 3 9816 0477. Email:
kellis@unimelb.edu.au. Received 2 Mar 2009; revision requested 6 Apr 2009; revised version received 24 Apr 2009; accepted 28 Apr 2009. First published online
27 May 2009.

672

AIBL: methodology and baseline characteristics

Introduction
The burgeoning global increase in the number of
people with dementia from around 26 million in
2005 to over 80 million by 2040 (Ferri et al.,
2005) presents a public health challenge of unprecedented magnitude. However, disease modifying
treatments with the potential to delay the onset
of the clinical symptoms of Alzheimer’s disease
(AD) (the commonest cause of dementia) are in
development. It is quite possible that one or more
of these potential treatments will be found to have
the capacity to delay the age at onset of AD in
susceptible individuals (Ritchie et al., 2007). In
Australia, where the number of people affected by
dementia is expected to triple from the current
234,000 (1% of the population) in 2009 to 731,000
(2.8% of the projected total population) by 2050,
delaying the onset of AD by 5 years could nearly
halve the total cost of dementia to society (Access
Economics, 2005).
If safe and effective disease modifying therapies
for AD emerge within the next decade (Ritchie
et al., 2007), it will be necessary to test whether
these therapies are efficacious in preventing or
delaying symptom emergence in those at high risk
of developing AD. Although some risk factors,
such as carrying an apolipoprotein E ε4 (ApoE
ε4) allele, have been found to raise an individual’s
chance of developing AD, current knowledge does
not permit us accurately to calculate the risk
of an individual (as opposed to a population)
developing AD at a particular time in the future.
To identify an appropriate population in which
preventative AD therapies could be trialed, we
need to identify biomarkers that can predict reliably
which individuals are likely to develop AD and over
what time period this may occur.
Putative biomarkers for the future development
of AD include the presence of brain amyloid
in asymptomatic individuals detected by Positron
Emission Tomography with Pittsburgh Compound
B (PiB PET imaging) (Rowe et al., 2007), levels of
Aβ42 amyloid and its precursors and metabolites
in plasma, and the ratio of tau and Aβ42 in the
cerebrospinal fluid (CSF) (Takeda et al., 2007).
In order to determine how well these and other
potential biomarkers may predict the risk and
timing of AD incidence, it is necessary to examine
cohorts of individuals who possess varying levels
of AD risk. Furthermore, such groups need to
be investigated and re-assessed prospectively over
long periods of time in order to establish who
will develop AD and when their symptoms will
appear. It also would be of significant benefit to
ascertain, in greater detail than is currently known,
which health and lifestyle factors protect against
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or contribute to the development of AD. The
extent to which these factors confer an increased or
decreased risk requires further investigation in order
to clarify how much variance in the incidence of AD
can be attributed to genetic endowment and how
much to other factors, and how different causative
and protective factors interact. Identification of
such factors might permit early treatment and
modification of risk factors to delay or defer the
onset of irreversible disease.
To this end, the Australian Commonwealth
Scientific Industrial and Research Organisation
(CSIRO) formed a partnership in late 2005 with
a number of leading researchers and research
organizations located in the Australian cities of
Melbourne and Perth (see Appendix 2). The aim
was to assemble a cohort of individuals who could
be assessed and followed at regular intervals and
whose tissues, amyloid brain load, and lifestyle
factors could be compared in relation to their
cognitive function (especially with respect to the
presence or absence of AD symptoms) and risk
factors. Our initial objective was to develop a cohort
of over 1000 individuals, at least 200 of whom
would have a current diagnosis of AD, and to assess
them at baseline and again after 18 months. We
intended to look for biological differences between
those with and without AD and then to follow the
cohort for many years to determine which putative
biomarkers, cognitive characteristics and health and
lifestyle factors determine subsequent development
of symptomatic AD. Further, we considered it
was important to dichotomize apparently healthy
individuals on the basis of whether they expressed
concern about their subjective memory function, as
there is disagreement in the literature as to whether
such subjective memory complaints are, or are not,
predictive of future cognitive decline (Jonker et al.,
2000; Glodzik-Sobanska et al., 2007; Reisberg,
2007; Reisberg and Gauthier, 2008).
We hypothesized that retrospectively crossreferencing putative blood biomarkers with both
longitudinal cognitive measures and the presence
or absence of brain amyloid detected by PiB PET
scanning would enable the identification of blood
biomarkers which detect the Alzheimer’s disease
process prior to the emergence of clear cognitive
symptoms. Further, we hypothesized that lifestyle
factors, such as exercise and diet (Lautenschlager
et al., 2008), would be associated to some degree
with cognitive outcome. The collaboration was
launched at a media event in November 2006, which
was used to appeal to volunteers aged 60 and over to
assist with the research project. This paper describes
the study methodology, including the assembly of
the cohort, and reports the baseline characteristics
of the participants in the Australian Imaging,
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Biomarkers and Lifestyle flagship study of aging
(AIBL study), including demography, medical
history, neuropsychology and mood measures.

Methods
We sought to recruit and characterize 1000
individuals from the following groups:
1. At least 200 individuals with AD as defined by
NINCDS-ADRDA criteria (McKhann et al., 1984).
2. At least 100 individuals with mild cognitive
impairment (MCI) – MCI is a clinical syndrome
characterized by reduced cognitive performance
(often involving memory), which represents a high
risk state for the development of frank AD (Petersen
et al., 1999; Winblad et al., 2004).
3. At least 700 healthy individuals without cognitive
impairment. This group included:
a. volunteers with at least one copy of the ApoE
ε4 allele,
b. volunteers without a copy of the ApoE ε4 allele,
c. volunteers who expressed subjective concern
about their memory function (“memory
complainers”; these individuals may belong to
either group a or b above). Memory complaints
were elicited by the response to the question:
“Do you have difficulties with your memory?”

Allocation of individuals to one of the three
diagnostic groups and exclusion of ineligible
individuals was undertaken by a clinical review
panel chaired by DA, details of which are outlined
below. When individuals presented with a diagnosis
of AD or MCI that had already been made by
a treating clinician, this diagnosis was reviewed
by the clinical review panel, in order to ensure
that diagnoses were made in a consistent manner
according to internationally agreed criteria.
The numbers to be recruited were in line with
other similar international cohorts and were largely
determined by available funding. It was agreed that
recruitment would cease once each of the specific
targets for each of the three diagnostic groups had
been attained.
The AIBL study was approved by the
institutional ethics committees of Austin Health, St
Vincent’s Health, Hollywood Private Hospital and
Edith Cowan University, and all volunteers gave
written informed consent before participating in the
study.
Telephone screening
Over 4000 individuals responded to a media
appeal for volunteers, while others volunteered
after their treating physician had informed them
about the AIBL study. All AIBL volunteers
underwent initial screening. The majority were

screened by telephone between December 2006
and February 2007, while a small number of
volunteers completed screening on the day of
their AIBL assessment. Questions included basic
demographic data (age, sex, contact details),
information about certain aspects of medical
history (diagnosed dementia, schizophrenia, bipolar
disorder, depression, Parkinson’s disease, cancer,
cardiovascular disease including stroke, diabetes,
alcohol intake), and whether they perceived any
difficulty with their current memory function.
The 15-item Geriatric Depression Scale (GDS15) (Brink et al., 1982; Yesavage et al., 1982;
Sheikh and Yesavage, 1986) was also completed.
Individuals who volunteered to take part were
excluded if they had a history of non-AD dementia,
schizophrenia, bipolar disorder, significant current
(but not past) depression (GDS score above
5/15), Parkinson’s disease, cancer (other than basal
cell skin carcinoma) within the last two years,
symptomatic stroke, uncontrolled diabetes, or
current regular alcohol use exceeding two standard
drinks per day for women or four per day for men.
Based on the screening interview, individuals
who were suitable for participation were invited
to attend for assessment. Assessments took place
between late 2006 and August 2008. Individuals
with diagnosed AD or MCI, and healthy individuals
who were aged over 75 years, were the first
participants invited for assessments. Baseline testing
continued until the target of assessing 200 AD
participants was reached, which took the total
cohort size to 1166 participants.
Attendance for AIBL assessment
Assessments took place at three locations in
Melbourne and at two locations in Perth, depending
on whether the participants were to undergo brain
imaging and where they lived. For a small number
of participants (especially for some of those affected
by AD), AIBL staff assessed them at home. Prior to
assessment, detailed information about the study
was sent to participants. Upon arrival, volunteers
discussed the study in detail with a senior member of
the research team before signing informed consent.
All assessments were conducted in the mornings,
after an overnight fast. Weight, height, abdominal
girth, sitting blood pressure and pulse were
measured, followed by the drawing of 80 ml of
blood. Participants were then provided with
breakfast, followed by cognitive and mood
assessments, as described below.
Cognitive and mood assessment
Cognitive and mood tests were performed by
trained staff, most of whom were qualified
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neuropsychologists. Some tests were selected on the
basis of their internationally acknowledged utility
and their ubiquity in the research literature (e.g.
the Mini-mental State Examination (MMSE) and
GDS). The tests comprising the neuropsychological
battery were selected on the basis that together they
covered the main domains of cognition that are
affected by AD and other dementias. These tests
were chosen so that results from our participants
were comparable with those from other similar large
studies, and all are internationally recognized as
having good evidence of their reliability and validity.
Readers who would like more information about our
test battery are invited to contact the corresponding
author by email.
The full battery comprised the MMSE (Folstein
et al., 1975), California Verbal Learning Test –
Second edition (CVLT-II) (Delis et al., 2000),
Logical Memory I and II (WMS; Story A only)
(Wechsler, 1945), D-KEFS verbal fluency (Delis
et al., 2001), 30-item Boston Naming Test (BNT)
(Saxton et al., 2000), Wechsler Test of Adult
Reading (WTAR) (Wechsler, 2001), Digit Span
and Digit Symbol-Coding subtests of the Wechsler
Adult Intelligence Scale – Third edition (WAIS–
III) (Wechsler, 1997), the Stroop task (Victoria
version) (Strauss et al., 2006), and the Rey
Complex Figure Test (RCFT) (Meyers and Meyers,
1995). The length of the assessment typically
ranged between one and two hours. Participants
also completed the computerized CogState battery
(www.cogstate.com) which took approximately
30 minutes to complete. The CogState battery
consists of five initial tasks displaying playing-card
stimuli. These include the Detection Task (reaction
time task measuring psychomotor function), the
Identification Task (choice reaction time task
measuring visual attention), the One Card Learning
Task (assessing visual recognition memory and
attention), and the One-Back Task (assessing
working memory and attention). For all tasks
speed (reaction time in milliseconds) and accuracy
(number of correct responses made) of each
performance were recorded. The final task
was the Continuous Paired Associate Learning
Task (assessing associate learning and memory);
accuracy of performance was calculated by totaling
the number of errors made in each round of the task.
In addition to GDS scores obtained at screening,
the Hospital Anxiety and Depression Scale (HADS)
(Snaith and Zigmond, 1986; Zigmond and Snaith,
1983) was completed. For participants with a
diagnosis of AD or MCI, an informant was asked to
provide additional information about the functional
performance of the research participant and to
complete the Informant Questionnaire on Cognitive
Decline (IQCODE) (Jorm and Jacomb, 1989).
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Dementia severity was rated for all participants
using the Clinical Dementia Rating scale (CDR)
(Morris, 1993), on the basis of information
obtained from cognitive testing, direct questioning
of the participant, and information from an
informant and/or from the participants’ treating
clinician (for those diagnosed with AD or MCI).
This scale, which assesses six domains of function
(memory, orientation, problem solving, home
and hobbies, community affairs, self care) is
scored according to a specific algorithm to
indicate whether dementia is absent (CDR = 0),
questionable (CDR = 0.5), mild (1), moderate (2)
or severe (3). Moreover, because six domain scores
ranging from 0 to 3 are generated on the CDR, it
is possible to calculate a “sum of the boxes” score
(ranging from 0 to 18).
Blood samples
Of the 80 ml of blood sample taken on arrival,
27 ml was forwarded to a clinical pathology
laboratory (Melbourne Health in Melbourne, and
PathWest Laboratory Medicine WA in Perth)
for baseline testing, which included full blood
examination, erythrocyte sedimentation rate, urea
and electrolytes, creatinine, androgen levels,
globulin levels, sex hormone binding globulin
(SHBG), glomerular filtration rate, calcium, liver
function tests, serum lipids, homocysteine, serum
and red cell folate, B12, glucose, insulin, ceruloplasmin, ferritin/transferrin/iron, estradiol, luteinizing
hormone, thyroid function (thyroid stimulating
hormone, free thyroxine, free triiodothyronine),
and prostate specific antigen (males only). One
0.5 ml tube of whole blood was forwarded for
apolipoprotein E genotyping. Another 0.5 ml of
whole blood was stored in liquid nitrogen. The
remaining blood was fractionated into the following
components: serum, plasma, platelets, red blood
cell, white blood cell (in dH2 0) and white blood
cell (in RNAlater, Ambion). These components
were stored in liquid nitrogen in 92 aliquots
(NUNC cryo-vials) which ranged in size from 0.25
ml to 1 ml. Stored blood samples were sourced
from three different tube types: lithium-heparin
tubes, EDTA tubes with added prostaglandin E1
(Sapphire Biosciences, 33.3 ng/ml), and serum
tubes.
Medical history and medication use
All participants completed a detailed questionnaire
regarding family medical history (including family
history of psychiatric disorders, dementia, and other
neurological illnesses), personal medical history,
medication use and smoking, and questions about
current and past alcohol and illicit drug use.
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Brain imaging
Funding was available for 250 participants to
undergo Magnetic Resonance Imaging (MRI) and
PET imaging with Pittsburgh Compound B (PiB),
an in vivo amyloid imaging agent. PiB imaging
methodology has been described previously (Pike
et al., 2007). 3D T1 MPRAGE and a T2 turbospin
echo and FLAIR sequence MRI was acquired
for screening and co-registration with the PET
images. PET standardized uptake value (SUV) data
acquired 40–70 minutes post-PiB injection were
summed and normalized to the cerebellar cortex
SUV, resulting in a region to cerebellar ratio termed
the SUV ratio (SUVR).
Health and lifestyle
All participants were asked to complete the International Physical Activity Questionnaire (IPAQ)
(Craig et al., 2003) and the Food Frequency
Questionnaire (FFQ) (Hodge et al., 2000). A
subset of the Perth cohort had their physical
activity recorded for seven days by a computerized
ActiGraph monitor. A subgroup from Perth also
underwent low dose radioactive (DEXA) scans to
assess body composition (including fluid, bone, and
adipose tissue).
Clinical review and the diagnosis of AD or
MCI
Monthly clinical review panel meetings were
conducted to discuss the baseline diagnostic
classification for all participants with a diagnosis
of AD or MCI, and for those who participated as
healthy controls who required further investigation.
This latter group included healthy participants
who demonstrated any of the following: MMSE
score <28/30, failure on the Logical Memory
test (as per ADNI criteria), other evidence
of possibly significant cognitive difficulty on
neuropsychological testing, a CDR score of 0.5 or
greater, a medical history suggestive of the presence
of illnesses likely to impair cognitive function, an
informant or personal history suggestive of impaired
cognitive function, or who were consuming
medications or other substances that could affect
cognition. A consensus diagnosis was assigned for
each such participant, which included consideration
of diagnostic criteria (DSM-IV diagnosis (American
Psychiatric Association, 1994) and ICD-10
diagnosis (World Health Organization, 1992))
and whether the subject violated any exclusion
criterion. Where appropriate, ICD-10 dementia
severity rating (World Health Organization, 1992),
NINCDS-ADRDA AD diagnosis (probable or
possible) and MCI classifications were applied. The
clinical review panel comprised old age psychiatrists

(DA, NL), a neurologist (DD), a geriatrician (MW)
and neuropsychologists (JF, KE, GS, KP, DDF). A
quorum was formed by three members including
at least one medically qualified and at least one
psychologist member. The panel conferred monthly
via telephone conference and most meetings were
attended by five or more participants. All but two of
these conferences were chaired by DA.
MCI diagnoses were made according to a
protocol based on the criteria of Winblad et al.
(2004) which are informed by the criteria of
Petersen et al. (1999). Consistent with Winblad
criteria, all participants classified with MCI had
either personally, or through an informant, reported
memory difficulties. Participants presenting with a
clinical diagnosis of MCI (i.e. previously diagnosed
by a clinician) were further required to demonstrate
a score 1.5 SD or more below the age-adjusted mean
on at least one neuropsychological task applied
at the time of the AIBL assessment in order to
be retained in the MCI category. Individuals who
volunteered to take part as healthy controls had to
fulfill the more stringent criterion of impairment
on two or more cognitive tests at a level at least
1.5 SD below the age-adjusted mean, in addition
to having reported memory difficulties, to be
classified as MCI. The greater stringency applied
to allocating individuals presenting as healthy
controls (HCs) to the MCI category was decided
upon after extensive discussion, and is justified by
the acknowledged mutability of MCI diagnoses.
Individuals were then characterized as amnestic
or non-amnestic, and single or multi-domain subtypes of MCI, on the basis of the specific tests
on which they had shown impaired performance.
All participants with MCI manifested substantially
intact activities of daily living and exhibited no clear
evidence of significant impairment in their social or
occupational functioning.
Statistical analyses
Statistical techniques to be used for analyzing data
generated by this cohort at follow-ups will be
described at a future date. Data reported here
were analyzed using the statistical package for
the social sciences (SPSS Inc., Chicago, IL) and
R version 2.8.1 (RDevelopmentCoreTeam, 2005).
Statistical measures included analyses of variance
(ANOVA), Kruskal-Wallis tests and other nonparametric statistical tests, employed according to
the characteristics of specific data elements, the
normality or otherwise of their distribution and their
suitability for comparison by statistical means. A
strength of the AIBL study is its collaboration with
the large and respected mathematical and statistical
division of CSIRO for future data analyses.

AIBL: methodology and baseline characteristics

Results
This section gives an overview of our initial
results across a range of measures and indicators,
but it should be noted that much more detail
will be included in subsequent, more specialized
publications, which will focus on specific aspects
of this cohort.

Composition of the AIBL cohort
Figure 1 shows the total numbers of volunteers
screened and assessed, the initial category to which
each volunteer or referred participant was assigned
prior to assessment, and the final category of
allocation after assessment and clinical review.
In all, 1166 individuals presented for AIBL
assessment. Fifty-four individuals were excluded,
resulting in a baseline cohort of 1112 participants.
These included 211 with NINCDS-ADRDA AD
(180 probable and 31 possible) and 133 who
met Winblad criteria for MCI (77 amnestic
multi-domain, 49 amnestic single-domain, 6 nonamnestic multi-domain, 1 non-amnestic singledomain). There were 768 “healthy control” (HC)
participants, of whom 396 complained about
their memory and 372 did not. Thirty-nine HC
individuals (3.5%) both reported and manifested
consistent slight forgetfulness or partial recollection
of events on testing and yet did not fulfill criteria for
MCI or dementia; these individuals were classed as
healthy controls with a CDR of 0.5.
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Of the 54 individuals (11 putative AD
participants, 18 presenting as diagnosed MCI
patients and 25 reporting to be healthy controls)
who presented for assessment but were unsuitable
for inclusion in the cohort, the most common
reasons for exclusion were excessive alcohol
consumption, past serious head injury, current
clinical depression, withdrawal of consent and
history of stroke(s). Specifically, volunteers were
excluded as follows: 16 volunteers had a history of
stroke(s), 6 had history of past serious head injury,
6 had excessive alcohol intake, 2 had epilepsy, 2 had
an existing diagnosis of frontotemporal dementia, 2
had Parkinson’s disease, 2 were taking morphine at
the time of assessment, 1 had a previous episode of
amnesia, 1 had previously been admitted to hospital
for hypoxia, 1 had insufficient English to complete
the assessment, 1 had depression not apparent
at screening, 5 volunteers did not have enough
information gathered at assessment (e.g. due to
advanced dementia), and 9 withdrew consent.
Within the inception cohort, 31 of the AD
participants were classified as having possible
(rather than probable) AD according to NINCDSADRDA criteria, due to the following reasons:
15 had a history or neuroimaging evidence of
asymptomatic minor stroke, TIA or recovered
head injury; 4 had current atrial fibrillation and/or
history of aortic aneurysm; 1 had Parkinsonian
symptoms and recently treated depression; 1 had
a previous (now revised) diagnosis of progressive
aphasia; 1 had epilepsy; 6 had abnormal blood

Figure 1. Composition of the AIBL cohort: screening, assessment and cohort sub-groups.
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pathology results (i.e. anemia, low folate, etc.); 1
reported previous excessive alcohol intake many
years prior to the development of AD; and 2 had
atypical clinical presentations of AD. For those
AD participants who reported excessive alcohol
intake, history of head injury, or past depression, the
clinical panel reviewed the cases in detail to ensure
that the dementing process occurred after, and in
isolation from, the possible confounding history.
For each of these 31 cases, the clinical review
panel determined that the dementia had clinical
AD features and that the potentially confounding
diagnosis or history did not appear to account for
the progressive dementing illness exhibited by the
study participants.
Following detailed review by the clinical panel, a
small proportion of AD and MCI cases did not meet
the relevant diagnostic criteria (NINCDS-ADRDA
criteria for probable or possible AD, or Winblad
criteria for MCI), and therefore were reallocated
to a different category. Specifically, eight putative
AD participants did not have significant impairment
of social or occupational functioning, and instead
fulfilled Winblad criteria for MCI. Three apparent
AD cases were reclassified as healthy control participants; two of these people had been diagnosed
with AD by clinicians relatively inexperienced in the
diagnosis and management of dementia, and one
had been incorrectly classified at presentation.
Consistent with previous research (Larrieu et al.,
2002; Solfrizzi et al., 2004; Kryscio et al., 2006),
MCI proved to be the most mutable diagnosis.
Thirty-three participants presenting with a diagnosis of MCI previously made by a clinician now
had significant impairment of social or occupational
functioning confirmed by informant history, and
a neuropsychological profile consistent with AD,
and therefore were reallocated to the AD category.
Twenty participants with an MCI diagnosis made
by the referral source did not demonstrate cognitive
functioning at least 1.5 SD below age-adjusted
norms on any cognitive tests, and were thus
reallocated at baseline to the healthy control group.
Seven participants who volunteered to take
part as healthy controls were found on testing
to have both cognitive deficits and an informant
history indicating significant impairment of social
or occupational functioning that met DSM-IV
and NINCDS-ADRDA criteria for AD. Fortysix participants who volunteered to take part as
healthy controls scored 1.5 SD below the ageadjusted mean on at least two cognitive assessment
measures, and either personally, or through an
informant, reported subjective memory difficulties,
but had substantially intact social and occupational
functioning. These 46 individuals were reallocated
to the MCI group.

Table 1. Baseline conﬁrmed classiﬁcation and
demographic characteristics for each group
HC

MCI

AD

...........................................................................................................................................................

N
Mean age (SD)
(years)
Gender (%male/
female)
Mean MMSE (SD)
CDR
Mean sum of
boxes (SD)
Mean overall
score (SD)
ApoE ε4 carriers (%)

768
70.0 (7.0)

133
75.7 (7.6)

211
78.0 (8.6)

43 / 57

44 / 56

38 / 62

28.9 (1.2)

26.2 (2.6)

19.0 (5.2)

0.03 (0.15) 1.23 (0.82) 5.72 (2.91)
0.03 (0.12) 0.50 (0.00) 1.00 (0.53)
27

51

63

HC = healthy controls
MCI = participants with Mild Cognitive Impairment
AD = participants with Alzheimer’s disease

Table 1 presents information about the 1112
individuals who formed the baseline AIBL cohort.
There was a greater percentage of females than
males in each group (HC = 57%, MCI = 56%,
AD = 62%). The AD participants had MMSE
scores ranging from 0 to 28 (median 20) and CDR
ratings consistent with “questionable” (CDR = 0.5;
68 AD participants), mild (CDR = 1; 114 AD),
moderate (CDR = 2; 25 AD) or severe (CDR = 3;
4 AD) dementia. All MCI participants had a CDR
of 0.5 and their MMSE scores ranged from 17 to
30 (median 26). Only two MCI volunteers had
a MMSE of less than 20, and these cases were
thoroughly reviewed by the clinical review panel.
The consensus decision for these cases was that
there were no significant difficulties with activities of
daily living. Both of these subjects had received only
limited schooling. The MMSE scores of healthy
controls ranged from 24 to 30 (median 29), and
all but 39 had a CDR of 0.
Figure 2 shows the age distribution of the cohort.
The healthy control participants were significantly
younger than the MCI and AD participants
(p<0.01). However the HC group was much larger
than the MCI and AD groups combined and
contained a substantial number of very elderly
healthy participants, which is sufficient to compare
AD and MCI participants with aged-matched
controls if and when necessary.
Demography
The majority of participants in the cohort were
either married (70% of HC, 57% of MCI, 60% of
AD) or widowed (11% of HC, 21% of MCI, 24% of
AD), and most participants primarily spoke English
at home (98% of HC, 92% of MCI, 91% of AD).
Those who spoke a language other than English at
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Figure 2. Age distribution for each group.

home were nevertheless fluent in English, as lack
of fluency in English was an exclusion criterion.
Involvement in organized community activities,
such as membership of Probus or senior citizen
clubs, Returned Servicemen’s League clubs and/or
sporting clubs was highest in the HC and MCI
groups, as was expected (68% of HC, 67% of MCI);
however, nearly half (47%) of AD patients remained
involved in community organizations at some level.
Approximately one third of the cohort reported
having at least one pet (33% HC, 28% of MCI,
33% AD). The cohort was well educated, with 47%
of HC, 58% of MCI and 42% of AD participants
reporting 13 or more years of education. Results
of the Wechsler Test of Adult Reading (WTAR)
revealed estimated mean premorbid IQ scores of
101 for AD patients, 105 for MCI participants and
108 for HCs, with significant differences between
each of the groups (HCs demonstrated significantly
higher mean IQ than MCIs, with ADs scoring
significantly lower than MCIs). The majority of
participants were right handed (88% of HC, 86% of
MCI, 87% of AD), in line with the world population
proportion of right-handedness (Corballis, 2009).

differed significantly on all measures (p<0.01).
Furthermore, planned comparisons demonstrated
that the HC group performed significantly better
than MCI participants, and MCI participants
significantly out-performed those with AD on all
measures (all p<0.01).
Table 3 presents the mean and standard deviation
of all measures of the CogState battery, and
the results of the Kruskal-Wallis significance test
for each measure. These findings demonstrate
significant differences between the three groups on
all measures (p<0.05). Further, Wilcoxon rankedsums tests showed that HC participants performed
significantly better than the MCI participants on all
measures of the CogState battery (p<0.0001). The
MCI participants performed significantly better
than the AD participants on the One Card Learning
task and the Continuous Paired Associate Learning
Task (p<0.05). There were no other significant
differences between the MCI and AD participants.
Overall, these cognitive findings were highly
consistent with those expected in participants
classified as HC, MCI and AD and support the
accuracy of participant assignment in this cohort.

Neuropsychology
Table 2 presents the mean and standard deviation
of normed and age-adjusted measures for the
neuropsychological tasks, and the results of
between-groups one-way analysis of variance
(ANOVA) for each measure. These groups

Baseline medical characteristics and
medication use
Table 4 presents vital signs (heart rate, blood pressure, weight, height and abdominal circumference
and body mass index) for the three groups. The
only difference between groups was observed in
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Table 2. Baseline cognitive performance measures for each group
A N OVA
HC
M

CVLT-II
T-score learning (1–5)
Short delay free recall
Z-score
Long delay free recall
Z-score
Recognition: true positives Z-score
Recognition: false positives Z-score
Recognition d’
LOGICAL MEMORY
Recall 1 raw score
Recall 2 raw score
Pass/Fail∗
RCFT
Copy Z-score
Short Recall Z-score
Long Recall Z-score
Recognition Z-score
DIGIT SPAN
Scaled score
DIGIT SYMBOL CODING
Scaled score
D-KEFS verbal fluency
FAS total Z-score
Category total Z-score
Fruit/Furniture total Z-score
Fruit/Furniture Switching Z-score
BNT
AU No cue Z-score
CLOCK raw score
WTAR estimated IQ
STROOP
Dots Z-score
Words Z-score
Colors Z-score
C/D Z-score

(SD)

MCI
M

(SD)

AD
M

(SD)

F

P

60.63 (10.93)
0.87 (1.01)

37.89 (9.74)
−1.39 (0.97)

26.28 (9.41)
−2.22 (0.66)

899.94
930.86

<0.001
<0.001

0.80 (0.98)

−1.64 (0.99)

−2.55 (0.64)

1128.80

<0.001

0.10 (0.83)
−0.21 (0.92)
0.47 (0.96)

−1.20 (1.47)
1.18 (1.39)
−1.23 (1.02)

−1.92 (1.92)
2.12 (1.87)
−2.04 (1.21)

247.48
304.14
513.57

<0.001
<0.001
<0.001

12.93 (3.88)
11.44 (4.02)
91/9%

6.42 (3.67)
3.83 (3.75)
31/69%

3.13 (2.80)
0.95 (1.98)
19/81%

623.95
720.38
713.96

<0.001
<0.001
<0.001

−0.49 (1.07)
0.50 (1.34)
0.54 (1.45)
0.32 (1.30)

−1.48 (2.06)
−0.81 (1.22)
−1.02 (1.49)
−1.19 (1.73)

−3.16 (3.49)
−1.91 (0.98)
−2.14 (1.03)
−2.94 (2.33)

157.29
273.37
279.39
294.27

<0.001
<0.001
<0.001
<0.001

12.03 (2.86)

11.06 (2.71)

9.07 (2.97)

83.93

<0.001

11.70 (2.59)

9.67 (2.88)

6.63 (2.95)

236.07

<0.001

12.05 (3.45)
12.40 (3.06)
12.16 (3.22)
12.18 (2.97)

9.96 (3.80)
8.92 (3.46)
8.15 (3.58)
8.50 (3.44)

7.31 (3.81)
5.25 (2.85)
4.55 (3.12)
5.05 (3.17)

139.75
424.34
417.88
411.18

<0.001
<0.001
<0.001
<0.001

0.75 (0.62)
9.76 (0.72)
111.60 (6.59)

0.18 (1.14)
9.29 (1.26)
108.80 (8.87)

−1.15 (1.94)
7.22 (2.38)
104.3 (12.37)

225.23
318.07
57.98

<0.001
<0.001
<0.001

−0.04 (1.20)
0.07 (1.15)
−0.33 (0.95)
−0.31 (0.83)

0.58 (1.92)
1.06 (2.12)
0.41 (1.63)
0.08 (1.04)

2.07 (4.84)
4.62 (10.74)
1.83 (3.68)
0.59 (1.72)

58.00
71.16
97.82
46.38

<0.001
<0.001
<0.001
<0.001

∗ Based

on education corrected cut-off scores for delayed recall of the first paragraph of the WMS Logical Memory subtest,
as defined by the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
CVLT-II = California Verbal Learning Test (second edition).
RCFT = Rey Complex Figure Test.
D-KEFS = Delis-Kaplan Executive Function System.
BNT = Boston Naming Test.
WTAR = Wechsler Test of Adult Reading (based on U.S. norms).
HC = healthy controls; MCI = participants with Mild Cognitive Impairment; AD = participants with Alzheimer’s disease.

the weight measures (p<0.05), with AD patients
weighing less than both HCs and MCIs. However,
this difference was mediated by age, with older
volunteers observed to weigh less than younger
volunteers (p<0.05).
With regard to family history of dementia, 28%
of AD participants reported that they had a first
degree relative with dementia. The mother was
the most common family member reported to
have had dementia (33 of 58; 57%). Of those

AD participants who reported a family history,
11 (19%) reported multiple first degree family
members to have had dementia. In the MCI group,
37% (49 participants) reported that they had a
first degree relative with dementia. Again, the most
common family member to have had dementia was
the participant’s mother (32; 65%). Of the MCI
participants who reported a family history, three
(6%) reported multiple first degree family members
to have had dementia. Family history of dementia in
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Table 3. Baseline CogState scores for each group – mean (SD)
KRUSKAL P
TA S K

HC

MCI

AD

WA L L I S H

.............................................................................................................................................................................................................................................................................................................................

Detection task reaction time (log10 transformed)
2.52 (0.12)
2.56 (0.14)
2.55 (0.09)
Identification task reaction time (log10 transformed)
2.71 (0.07)
2.76 (0.09)
2.77 (0.1)
One Card Learning Task accuracy (arcsine transformed) 1.02 (0.11)
0.93 (0.11)
0.85 (0.1)
One-Back Task accuracy (arcsine transformed)
1.33 (0.15)
1.21 (0.16)
1.13 (0.14)
One-Back task reaction time (log10 transformed)
2.93 (0.09)
3.02 (0.08)
3.03 (0.11)
CPAL (errors)
39.07 (26.33) 61.77 (26.18) 82.33 (32.26)

8.68
22
42.29
32.4
39
58.38

<0.05
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

HC = healthy controls
MCI = participants with Mild Cognitive Impairment
AD = participants with Alzheimer’s disease

Table 4. Mean (SD) vital sign measures for each group
HC

MCI

AD

...............................................................................................................................................................................................................

Height (cm)
Weight (kg)
Blood pressure systolic (mm Hg)
Blood pressure diastolic (mm Hg)
Heart rate (bpm)
Abdominal circumference (cm)
Body Mass Index (BMI)

166.6 (11.2)
74.2 (15.0)
137.9 (15.4)
78.6 (9.7)
67.1 (10.1)
91.4 (15.2)
27.4 (18.9)

165.5 (8.7)
70.2 (12.4)
141.0 (14.6)
79.1 (10.2)
67.4 (9.3)
90.8 (12.4)
25.6 (3.9)

164.8 (9.5)
66.7 (13.3)
138.1 (15.6)
80.0 (11.1)
68.0 (10.1)
91.7 (12.0)
24.8 (4.4)

HC = healthy controls
MCI = participants with Mild Cognitive Impairment
AD = participants with Alzheimer’s disease

the HC group was also common. Three-hundredand-twenty-eight (43%) HC participants reported
that they had a first degree relative with dementia;
175 (53%) were memory complainers, 153 (47%)
were not memory complainers. Forty-two (13%)
HC participants reported that they had multiple
first degree relatives with dementia. As with the AD
and MCI participants, the most common family
member reported by the HC participants to have
had dementia was their mother (228; 70%).
Table 5 presents self-reported current and past
medical history. Participants from all three groups
had a range of comorbid medical conditions,
including current or past history of hypertension
(297 HC, 52 MCI, 48 AD), diabetes mellitus (53
HC, 14 MCI, 23 AD), treated thyroid disease (82
HC, 11 MCI, 16 AD) and gastrointestinal system
complaints (250 HC, 35 MCI, 44 AD).
Prescription and “over the counter”
medication
Most participants, regardless of classification,
reported taking medications. Overall, 79% of
HC, 87% of MCI and 97% of AD participants
were taking at least one prescription or over the
counter medication. The proportion of participants
taking medications was significantly greater in the
AD group than the MCI group, with the HC

group having the significantly lowest proportion of
participants taking medications.
Participants took between 0 and 13 medications per day (average intake: HC = 2.4 + 2.2,
MCI = 3.2 + 2.6, AD = 3.8 + 1.2), and again there
were significant differences between the groups,
with AD participants taking more medications daily
than MCI participants, and HCs taking the least
number of medications.
Consistent with the high levels of cholesterol
in this age-group, the most commonly prescribed
medication for all participants was the cholesterollowering agent atorvastatin calcium (107 HC, 19
MCI, 30 AD). Occasional paracetamol and/or aspirin were also within the top ten medications listed
by all three groups (166 HC, 38 MCI, 63 AD).
Of the 211 confirmed AD participants, 134
(64%) were prescribed AD medication at the time
of assessment. The most common AD medication
was donepezil (74 AD patients), followed by galantamine (43 patients), and rivastigmine (5 patients).
An additional six patients were taking a combined
donepezil/memantine treatment, and six were taking combined galantamine/memantine treatment.
Although there were 77 AD volunteers who were
not taking AD medications at baseline, it should
be noted that this group includes 33 participants
who presented as MCI and six participants
who presented as HC (and were subsequently
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Table 5. Percentage of participants in each group
who reported current or past history of speciﬁc
medical conditions

Table 6. Baseline anxiety and depression scores on
the HADS and GDS measures for each group.
A N OVA

HC

MCI

HC

AD

.....................................................................................................................................................

Hypertension
Myocardial infarction
Diabetes mellitus
Visual Color Deficit
Cancer∗
History of falls
Thyroid disease
Gastrointestinal disorders
Arthritis
Joint replacement
Liver disease including hepatitis
Kidney disease
Depression
Anxiety
Other psychiatric disorders

38.9
4.6
6.9
3.4
17.1
11.1
10.7
32.6
51.4
10.7
4.4
7.7
15.4
15.0
1.3

39.1
5.3
10.5
1.5
15.0
25.6
8.3
26.3
48.1
12.8
5.3
9.0
23.3
23.3
3.8

37.4
6.2
10.9
2.8
15.2
22.7
7.6
20.9
42.7
9.5
1.9
3.8
27.0
23.2
3.8

∗ Most

were skin cancers. Those that were not (e.g. bowel cancer)
had been cured or had been in remission for more than 2 years.
# Most often gastro-esophageal reflux or diverticular disease.
HC = healthy controls; MCI = participants with Mild Cognitive
Impairment; AD = participants with Alzheimer’s disease.

reallocated to the confirmed AD group after clinical
panel review). Of the 33 volunteers who presented
as MCI and were subsequently classified as AD,
four were taking donepezil and nine were taking
galantamine at the time of assessment. In addition,
several of the AD participants who presented as AD
and who were not on AD therapy had been recently
diagnosed and had not yet started their treatment.
One subject who presented having been
diagnosed with AD by a practitioner inexperienced
in its diagnosis and management was taking
donepezil, despite the clinical review panel
observing no evidence of impairment in either their
past or current social and occupational functioning,
or in their cognitive profile, and this participant
was reallocated to the HC group. Finally, one AD
patient who was misclassified as HC at presentation
was taking donepezil.
The AD group had a significantly higher
proportion of antidepressant use (6% HC,
15% MCI, 25% AD). The reported intake of
benzodiazepines was low in all groups (2% HC, 6%
MCI and 6% AD), with most using them on an “as
required” basis.
Nutraceuticals
A large proportion of the cohort was taking
nutraceuticals (i.e. vitamins, minerals, herbs and
other supplements). The number of nutraceuticals
taken daily ranged from 0 to 13 (HC = 1.7 + 2.0,
MCI = 1.3 + 1.8, AD = 1.1 + 1.6), and the proportion of HCs taking nutraceuticals was significantly

M

(SD)

MCI
M

(SD)

AD
M

(SD)

F

P

......................................................................................................................................................

HADS
A
4.4 (2.9)
D
2.6 (2.3)

4.9 (2.9)
3.7 (2.6)

4.9 (3.9)
4.0 (3.7)

4.29
28.52

<0.001
<0.001

GDS

2.0 (1.8)

2.9 (2.2)

91.11

<0.001

2.0 (1.4)

HADS scores can range from 0 – 18. GDS scores can range from
0 – 15.
HADS = Hospital Anxiety and Depression Scale (A = anxiety
subscale score, D = depression subscale score).
GDS = Geriatric Depression Scale.
HC = healthy controls; MCI = participants with Mild Cognitive
Impairment; AD = participants with Alzheimer’s disease.

higher than in the AD group. Vitamin supplements
were the most commonly reported item taken
by all participants, with over half the cohort
(HC = 60%, MCI = 52%, AD = 53%) taking a
vitamin supplement.
Symptoms of depression and anxiety
Table 6 shows GDS and HADS measures for the
three groups. While the mean scores for each group
were low (suggesting low levels of anxiety and
depression) due to exclusion of high GDS scorers
in the HC group at screening, analysis of variance
demonstrated that MCI and AD participants
tended to be have significantly more symptoms of
anxiety and depression than HC participants (all
p < 0.05).
Forty (5.3%) HC participants scored within the
clinically significant range on the anxiety subscale of
the HADS (i.e. ≥10/18) and a further 121 (15.9%)
had scores within the probably clinically significant
range (i.e.7–9). Ten (1.3%) HC participants scored
within the clinically significant range on the
depression subscale (i.e. ≥10/18) and a further 37
(4.9%) had scores within the probably clinically
significant range (i.e. 7–9).
Consistent with many previous research publications (Jost and Grossberg, 1996;Mega et al.,
1996;Lyketsos et al., 2002; Rozzini et al., 2008),
current and past historyof depression and anxiety
rates were higher in the AD and MCIgroups, compared to HCs (15% of HC, 23% of MCI and 27%
of AD participants reported current or past depression; 14% of HC, 23% of MCI and 23% of AD participants reported current or past history of anxiety).
Blood samples
A summary of ApoE genotyping results is
presented in Table 1. As expected, the number
of ApoE ε4 carriers was highest in the AD
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group (HC = 27%, MCI = 51%, AD = 63%), with
significant differences between the groups.
PiB imaging
Two-hundred-and-eighty-seven participants (53
AD, 57 MCI, 177 HC) had a 11C-PiB-PET scan,
as previously described (Pike et al., 2007) and a
3D T1-weighted MPRAGE, T2 FSE, and FLAIR
sequence MRI for screening and co-registration
with the PET images.
Health and lifestyle
A total of 100 AIBL participants (16 AD, 20 MCI
and 64 HC) underwent DEXA scans. In addition,
91 participants participated in the ActiGraph
monitoring component (6 AD, 8 MCI and 77 HC).
There were 31 participants who completed both
DEXA and ActiGraph components (2 AD, 1 MCI
and 29 HC).

Discussion
The AIBL study has assembled a large cohort of
individuals who can be assessed, compared and
then followed over a long period of time in order
to facilitate prospective research into AD. This is
the largest cohort study of its kind in Australia (and
one of the largest worldwide) to have thoroughly
assessed individuals with and without AD, and
with varying levels of risk for developing AD. The
participants represent a group of highly motivated
and well-characterized individuals whose cognitive
data, blood samples, imaging results, and lifestyle
information will be examined longitudinally at
regular intervals.
Classifications of AD and MCI within the
cohort were made according to established,
internationally recognized criteria after thorough
review by a multi-disciplinary group of academic
clinicians experienced in the assessment, diagnosis
and management of late-life cognitive disorders,
particularly AD and MCI. Most participants who
presented with diagnoses of AD from their treating
clinician had these diagnoses confirmed by the
clinical review panel, demonstrating the relatively
robust nature of this clinical diagnosis and the
expertise of the referring clinicians. In contrast,
MCI cases were by far the most difficult group to
characterize. A significant percentage of those who
presented with an MCI diagnosis from their treating
clinician proved not to fulfill internationally-agreed
MCI criteria (Winblad et al., 2004). However,
it is possible that the referring clinicians were
using different diagnostic criteria from Winblad and
colleagues, as these have changed with time and are
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evolving more rapidly than AD diagnostic criteria.
Also, it is known that some individuals classified as
having MCI will progress to exhibiting clear symptoms of AD within months, while some others will
show cognitive improvement over time (Petersen
et al., 1999). The reliability of the current MCI
diagnostic classifications needs to be tested over
time. The AIBL cohort represents an opportunity to
examine the biological, imaging or lifestyle markers
which may be of use in clinical classification. Using
the standard criteria (as employed in this study), we
would expect to see progression to AD from MCI in
10–20% of this group annually, with approximately
one-third of MCI cases never progressing to AD.
Both the rate of ApoE ε4 allele frequency in the
MCI group compared to our AD and HC groups,
and the neuropsychological testing results of the
MCI group, suggest that we have identified a
group of individuals whose characteristics are, in
many respects, intermediate between HC and AD
participants.
In this study the term HC referred predominantly to the absence of cognitive difficulties.
As expected in a group of over 700 individuals
aged between 60 and 96, most were affected
by one or more chronic but controlled medical
conditions, and a past history of some degree
of depression or anxiety was common. Our HC
participants were taking a range of medications
and had medical histories which indicated the
presence of a range of medical conditions typical
of this age group. Where HC participants had
evidence of illnesses or medication use that could
have affected cognitive function, their cases were
reviewed in detail. For example, we were careful
to ensure that individuals with a history of
hypothyroidism were taking thyroxine and had
normal TSH levels. Most antidepressants taken
were types that do not usually affect cognition.
For the small proportion of individuals who were
taking benzodiazepines, dosage was typically low,
often taken only occasionally, and cognition was
nevertheless within normal limits on testing. HC
participants who were assessed as performing
poorly on cognitive tests due to current medical
illness, medical history or medication use were
excluded from the cohort as noted in the study
methodology. It would have been possible to
exclude all HC individuals who had recovered
from previous depression, or were affected by
hypertension (or any other illness associated with
an increased risk of current cognitive impairment
or future decline), or to have denied participation
to all who took any psychotropic drugs. However,
this would have resulted in the selection of a “supernormal” cohort of individuals chosen for extreme
health, whose parameters would not have been
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comparable with those of our AD and MCI groups.
The characteristics of the current cohort of HCs
therefore allow for a better comparison between
groups based on their similar medical histories.
The term HC may be a misnomer when applied
to this large group of individuals with a range of risk
factor profiles for AD. This point notwithstanding,
the neuropsychology results obtained from our
HC participants give an excellent baseline against
which to detect even subtle future changes.
Tracking change in this group over time should
provide valuable information regarding the profiles
(biological, psychological, medical, social and
genetic) of individuals aged over 60 who are most
likely to develop AD, in addition to offering an
important insight into rates of change in cognition
and other measures over time in healthy elderly
people. Of specific interest will be the differences (if
any) seen between those HCs who are “subjective
memory complainers” and those HCs who do
not report memory concerns. To date there
is conflicting evidence as to whether subjective
memory impairment is associated with an increased
risk for developing cognitive impairment (for a
review, see Jonker et al., 2000). Fifty-two percent
of the HCs in this cohort were subjective memory
complainers, which is in line with prevalence of
memory complaint assessed in other communitybased studies, with rates ranging from a quarter to
over a half of healthy volunteers (Jonker et al., 2000).
It should be noted that this cohort was recruited
through advertisements seeking volunteers for a
study into memory and aging, and there is likely
to have been some inherent self-selection bias
towards those with a family history of dementia
who might be expected to exhibit more interest in
such research than individuals with no exposure
to dementia in their family members. However,
proportions of ApoE ε4 carriers in this cohort were
consistent with previous estimates of the Australian
population (Corbo and Scacchi, 1999; Martins
et al., 1995) and do not suggest a significant
over-selection of ε4 carriers.
Subsequent detailed analysis of the baseline
cross-sectional data presented here will provide
valuable information on links between cognition,
brain amyloid burden, structural brain changes,
biomarkers, and lifestyle. The future research yield
from the AIBL cohort should add much to our
knowledge about AD. Currently, 18-month followup assessments are taking place, and, in addition
to repeating baseline assessments participants are
being asked to give consent to future post mortem
brain donation and autopsy so that plaque and
tangle counts as well as total brain amyloid burden
can be determined in due course for at least
one quarter of the cohort. The existence of a

well-established Australian brain donation network
will facilitate this goal. At 18-month follow-up at
least 100 participants will donate CSF obtained
at lumbar puncture to permit determination of
Aβ/tau ratios in CSF and to cross-validate PiB PET
findings and Aβ blood amyloid levels. Dependent
on continued funding, all consenting members of
this cohort will be followed at 18-month intervals
until death, with the primary aim of determining
which baseline characteristics are predictive of
future cognitive decline. The cluster collaboration
demonstrates the increased capacity for recruitment
with multicenter collaboration necessary to achieve
large sample size with in-depth clinical examination.
In addition, the cluster strategy with specialized
researchers within broad themes allows the benefit
of a combination of skills from clinical expertise to
basic science and bioinformatics.
The AIBL dataset is a unique Australian resource
with international significance, which will assist
development of important and robust techniques
for early detection of AD, identify lifestyle targets
which may delay onset of AD, and provide a valuable
cohort suitable for further study of AD.
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